Physicians' Academy for Cardiovascular Education

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - Amsterdam, The Netherlands - AHA 2019, Philadelphia

Note: The GALILEO trial included 1644 patients, who were randomized to a strategy of rivaroxaban with aspirin for 90 days followed by rivaroxaban alone or an antiplatelet-regime consisting of clopidogrel with aspirin for 90 days followed by aspirine alone.

Educational information

This video was recorded at the AHA in Philadelphia, USA, on november 17, 2019.


Prof. Freek Verheugt is cardiologist and lives in Amsterdam, The Netherlands.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Read our summary of the GALILEO trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: